Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 3,585 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma, Bronchogenic Clear all
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

NCT07541170
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Divarasib, Pembrolizumab, Nivolumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
6
States / cities
Clovis, California • Atlanta, Georgia • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 16, 2026, 3:12 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

NCT03937154
View directory record Official record
Conditions
Chemotherapy-induced Thrombocytopenia
Interventions
Romiplostim, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
27
States / cities
Jonesboro, Arkansas • Anaheim, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 16, 2026, 3:12 AM EDT
Recruiting Phase 1 Interventional

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

NCT04686305
View directory record Official record
Conditions
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
T-DXd, Durvalumab, Cisplatin, Carboplatin, Pemetrexed, Volrustomig, Rilvegostomig
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Duarte, California • Newport Beach, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 16, 2026, 3:12 AM EDT
Completed Phase 1 Interventional

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

NCT00633529
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
IMO-2055
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
9
States / cities
Ocoee, Florida • Indianapolis, Indiana • Albany, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Oct 16, 2026, 3:12 AM EDT
Completed Phase 1 Interventional

Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00072072
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib, erlotinib hydrochloride
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 16, 2026, 3:12 AM EDT
Completed Phase 1 Interventional

Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies

NCT01242072
View directory record Official record
Conditions
Malignancy, Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Testicular Cancer, Thymoma, Ovarian Cancer, Osteosarcoma
Interventions
palifosfamide-tris
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Indianapolis, Indiana • Lafayette, Indiana • Muncie, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 16, 2026, 3:12 AM EDT
Not listed Not applicable Interventional

Active Surveillance in Early Lung Cancer

NCT03923777
View directory record Official record
Conditions
Stage IA Non-small Cell Lung Cancer, Lung Carcinoid Tumor
Interventions
Active Surveillance
Other
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
65 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 16, 2026, 3:12 AM EDT
Completed Phase 1 Interventional

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

NCT01069328
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer
Interventions
Nexavar (Sorafenib, BAY43-9006), Bevacizumab, Paclitaxel, Carboplatin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Oct 16, 2026, 3:12 AM EDT
Completed Phase 2 Interventional

Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer

NCT00039507
View directory record Official record
Conditions
Lung Cancer
Interventions
conventional surgery, radiofrequency ablation
Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2010 · Synced Oct 16, 2026, 3:12 AM EDT
Active, not recruiting Phase 3 Interventional

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774
View directory record Official record
Conditions
Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Interventions
Tarlatamab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
18
States / cities
Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 16, 2026, 3:12 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

NCT05799274
View directory record Official record
Conditions
Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
RAD301 ([68Ga]-RAD301)
Drug
Lead sponsor
Radiopharm Theranostics, Ltd
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Princeton, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 16, 2026, 3:12 AM EDT
Terminated Phase 2 Interventional Results available

Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer

NCT02410382
View directory record Official record
Conditions
Head and Neck Cancer, Non-small Cell Lung Cancer
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 16, 2026, 3:12 AM EDT
Completed Not applicable Interventional Results available

Study of Tarceva and Targretin in Stage I-II Lung Cancer

NCT00125372
View directory record Official record
Conditions
Carcinoma, Non-small-cell Lung
Interventions
erlotinib (Tarceva) and bexarotene (Targretin)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 16, 2026, 3:12 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

NCT03829501
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer, Gastric Cancer, Melanoma, Renal Cell Carcinoma, Pancreatic Cancer, Cervical Cancer, Triple Negative Breast Cancer, Advanced Cancer, Metastatic Cancer
Interventions
Alomfilimab, Atezolizumab
Drug
Lead sponsor
Kymab Limited
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Duarte, California • New Haven, Connecticut • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 16, 2026, 3:12 AM EDT
Terminated No phase listed Observational

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

NCT04698681
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Mutation, NFE2L2 Gene Mutation
Interventions
Not listed
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 16, 2026, 3:12 AM EDT
Completed Phase 2 Interventional Results available

Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

NCT01533181
View directory record Official record
Conditions
Recurrent Small Cell Lung Carcinoma
Interventions
Laboratory Biomarker Analysis, Linsitinib, Pharmacological Study, Topotecan Hydrochloride
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 16, 2026, 3:12 AM EDT
Completed Phase 1 Interventional

Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT00004095
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer
Interventions
gemcitabine hydrochloride, irinotecan hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 16, 2026, 3:12 AM EDT
Completed Phase 2 Interventional

Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy

NCT00379665
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cisplatin
Drug
Lead sponsor
Southwestern Regional Medical Center
Other
Eligibility
20 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 16, 2026, 3:12 AM EDT
Completed Phase 1Phase 2 Interventional

Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

NCT00062270
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, docetaxel, gefitinib, gemcitabine hydrochloride, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 16, 2026, 3:12 AM EDT
Completed Phase 1 Interventional

A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)

NCT00102505
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Carcinoma, Bronchogenic
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2009 · Synced Oct 16, 2026, 3:12 AM EDT
Withdrawn Early Phase 1 Interventional

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

NCT02277457
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
PET-Adaptive RT, Erlotinib, Crizotinib
Radiation · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 16, 2026, 3:12 AM EDT
Terminated Phase 1 Interventional

A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

NCT04849273
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer, NSCLC, Advanced Solid Tumor, Metastatic Solid Tumor, ALK Gene Mutation
Interventions
TPX-0131
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Orange, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 16, 2026, 3:12 AM EDT
Recruiting Phase 2 Interventional

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

NCT06623656
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cemiplimab, Platinum based chemotherapy, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 16, 2026, 3:12 AM EDT
Active, not recruiting Phase 1 Interventional

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

NCT05653882
View directory record Official record
Conditions
Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
Interventions
etakafusp alfa (AB248), pembrolizumab
Biological
Lead sponsor
Asher Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
20
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 16, 2026, 3:12 AM EDT